Comparison of tumor markers and clinicopathological features in serous and mucinous borderline ovarian tumors

Objective: The aim of this study was to assess tumor markers and clinicopathological findings of patients with serous and mucinous borderline ovarian tumor (BOT) features. Methods: The study consisted of 50 patients that were diagnosed with and treated for BOT between 2005- 2010 in three centers. CA125, CA19-9, and CA125+CA19-9 levels and clinicopathological features were compared in serous and mucinous histotypes. In serous and mucinous BOTs, correlations between tumor markers and demographics such as age, menopausal status, parity, clinical findings (stage, relapse, adjuvant chemotherapy, cytology, lymph node involvement and tumoral morphology (cystic-solid content, papilla, septation) were evaluated. Results: There were no significant differences between serous and mucinous tumors in the clinicopathological features such as stage, tumor markers, age, menopausal status, or cytology. In serous BOTs we found a significant relation between elevated CA 125+ CA 19-9, CA 19-9 and recurrence (p < 0.05). Also there was a significant relation between elevated CA 125+ CA 19-9, CA 19-9 and cytology positivity (p < 0.05). We found a significant relation in serous BOTs between elevated CA125+CA19-9, adjuvant chemotherapy and lymph node metastases (p < 0.05). Also In mucinous BOTs with papilla formation we found a significant relation between elevated CA125 and CA 125+ CA19-9 (p < 0.05). There was significant relation between cytology positivity and elevated CA 19-9 in mucinous BOTs (p < 0.05). Conclusion: Serum tumor markers of serous and mucinous BOTs were different in relation to their clinicopathological features. This may reflect differences of serous and mucinous BOTs.

Borderline ovarian tumor; Serous; Mucinous borderline ovarian tumor; Tumor markers

[1] Taylor H.C.: “Malignant and semimalignant tumors of the ovary”. Surg. Gynecol. Obstet., 1929, 48, 204.

[2] International Federation of Gynecology and Obstetrics Classification and staging of malignant tumors in the female pelvis.Acta Obstet. Gynecol. Scand., 1971, 50, 1.

[3] Tinelli R., Tinelli A., Tinelli F.G., Cicinelli E., Malvasi A.: “Conservative surgery for borderline ovarian tumors: a review”. Gynecol. Oncol., 2006, 100, 185.

[4] Cadron I., Leunen K., Van Gorp T., Amant F., Neven P., Vergote I.: “Management of borderline ovarian neoplasms”. J. Clin. Oncol., 2007, 25, 2928.

[5] Tinelli R., Malzoni M, Cosentino F., Perone C., Tinelli A., Malvasi A. et al.: “Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors”. Fertil. Steril., 2009, 92, 736.

[6] Benito V., Lubrano A., Arencibia O., Medina N., Alvarez Eva E., Andujar M. et al.: “Serous and mucinous borderline ovarian tumors: are there real differences between these two entities”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010, 153, 188.

[7] Tamakoshi K., Kikkawa F., Shibata K., Tomoda K., Obata N.H., Wakahara F. et al.: “Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor”. Gynecol. Oncol., 1996, 62, 67.

[8] Gotlieb W.H., Soriano D., Achiron R., Zalel Y., Davidson B., Kopolovic J. et al.: “CA125 measurement and ultrasonography inborderline tumors of the ovary”. Am. J. Obstet. Gynecol., 2000, 183, 541.

[9] Engelen M., Bruijn H., Hollema H., Ten Hoor K., Willemse P., Aalders J. et al.: “Serum Ca 125, Carcinoembryogenic antigen and Ca 19. 9 as tumor markers in borderline ovarian tumors”. Gynecol. Oncol., 2000, 78, 16.

[10] Ayhan A., Guven S., Guven E.S., Kucukali T.: “Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?”. Acta Obstet. Gynecol. Scand., 2007, 86, 484.

[11] Kolwijck E., Chris M.G.T., Bulten J., Leon F.A.G. Massuger: “Preoperative CA-125 levels in 123 patients with borderline ovarian tumors a retrospective analysis and review of the literature”. Int. J. Gynecol. Cancer, 2009, 19, 1335.

[12] Shih K.K., Zhou Q., Huh J, Morgan J.C., Iasonos A., Aghajanian C. et al.: “Risk factors for recurrence of ovarian borderline tumors”. Gynecol. Oncol., 2011, 120, 480.

[13] Poncelet C., Fauvet R., Yazbeck C., Coutant C., Darai E.: “Impact of serum tumor marker determination on the managementof women with borderline ovarian tumors: Multivariate analysis of a French multicentre study”. EJSO, 2010, 36, 1066.

[14] FIGO Committee on Gynecologic Oncology: “Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia”. Int. J. Gynecol. Obstet., 2009, 105, 3.

[15] Acs G.: “Serous and mucinous borderline (low malignant potential) tumors of the ovary”. Am. J. Clin. Pathol., 2005, 123, S13.

[16] Ren J., Peng Z., Yang K.: “A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors”. Gynecol. Oncol., 2008, 110, 162.

[17] Kikkawa F., Nawa A., Kajiyama H., Shibata K., Ino K., Nomur S.: “Clinical characteristics and prognosis of mucinous tumors of the ovary”. Gynecol. Oncol., 2006, 103, 171.

[18] Wu T.I., Lee C.L., Wu M.Y., Hsueh S., Huang K.G., Yeh C.J. et al.: “Prognostic factors predicting recurrence in borderline ovarian tumors”. Gynecol. Oncol., 2009, 114, 237.

[19] Lenhard M.S., Nehring S., Nage D., Mayr D., Kirschenhofer A., Hertlein L. et al.: “Predictive value of CA 125 a nd CA 72-4 in ovarian borderline tumors”. Clin. Chem. Lab. Med., 2009, 47, 537.

[20] Rice L.W., Lage J.M., Berkowitz R.S., Goodman A., Muto M.G., Knapp R.C. et al.: “Preoperative serum CA-125 levels in border-line tumors of the ovary”. Gynecol. Oncol., 1992, 46, 226.

[21] Cadron I., Amant F., Van Gorp T., Neven P., Leunen K., Vergote I.: “The management of borderline tumours of the ovary”. Curr. Opin. Oncol., 2006, 18, 488.

[22] Fadare O.: “Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors)”. Int. J. Gynecol. Cancer, 2009, 19, 103.

[23] Exacoustos C., Romanini M.E., Rinaldo D., Amoroso C., Szabolcs B., Zupi E., Arduni D.: “Preoperative sonographic features of bor-derline ovarian tumors”. Ultrasound Obstet. Gynecol., 2005, 25, 50.

[24] Pascual M.A., Tresserra F., Grases P.J., Labastida R., Dexeus S.:“Borderline cystic tumors of the ovary: gray-scale and color Doppler sonographic findings”. J. Clin. Ultrasound, 2002, 30, 76.